Loading clinical trials...
Loading clinical trials...
The purpose of this study was to assess immunogenicity of a 3-dose versus 4-dose infant vaccination schedule including kinetics of immune response in the early phases of the series.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Novartis Vaccines
NCT06131554 · Meningococcal Meningitis
NCT01725217 · Meningococcal Disease
NCT02955797 · Meningitis, Meningococcal Meningitis, and more
NCT02842853 · Meningitis, Meningococcal Meningitis, and more
NCT02842866 · Meningitis, Meningococcal Meningitis, and more
Birmingham, Alabama
Fayetteville, Arkansas
Jonesboro, Arkansas
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions